Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down – Should You Sell?

by · The Cerbat Gem

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $22.20, but opened at $21.08. Sarepta Therapeutics shares last traded at $21.1410, with a volume of 2,028,427 shares trading hands.

Analyst Ratings Changes

SRPT has been the topic of several recent research reports. Robert W. Baird decreased their price objective on Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating on the stock in a report on Tuesday, November 4th. BMO Capital Markets raised shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $50.00 price objective for the company in a research note on Monday, September 22nd. Mizuho upgraded Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $19.00 to $26.00 in a report on Wednesday, November 5th. Guggenheim dropped their price objective on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sarepta Therapeutics in a research note on Monday. Nine analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $33.68.

View Our Latest Stock Analysis on Sarepta Therapeutics

Sarepta Therapeutics Trading Down 1.0%

The company has a current ratio of 2.95, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78. The firm has a market cap of $2.26 billion, a PE ratio of -7.15 and a beta of 0.54. The company has a 50-day simple moving average of $20.93 and a 200 day simple moving average of $21.11.

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last announced its quarterly earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). Sarepta Therapeutics had a negative return on equity of 4.85% and a negative net margin of 11.25%.The firm had revenue of $399.36 million for the quarter, compared to analysts’ expectations of $331.51 million. During the same period last year, the company posted $0.62 earnings per share. The business’s quarterly revenue was down 14.5% on a year-over-year basis. As a group, sell-side analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of hedge funds have recently bought and sold shares of the business. iSAM Funds UK Ltd acquired a new position in shares of Sarepta Therapeutics during the 3rd quarter worth approximately $25,000. Ancora Advisors LLC raised its position in Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 1,000 shares during the period. Byrne Asset Management LLC purchased a new position in Sarepta Therapeutics during the third quarter valued at $33,000. Allworth Financial LP increased its stake in shares of Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 1,721 shares in the last quarter. Finally, Parallel Advisors LLC raised its position in shares of Sarepta Therapeutics by 165.3% during the 3rd quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 1,256 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

(Get Free Report)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Featured Stories